The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
Open accessAbstract
BACKGROUND: Potential drug-drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment. We assessed the prevalence and seriousness of potential PDDIs among ambulatory cancer patients on oral anticancer treatment. METHODS: A search was conducted in a computer-based medication prescription system for dispensing oral anticancer drugs to outpatients in three Dutch centres. Potential drug-drug interactions were identified using electronic (Drug Interaction Fact software) and manual screening methods (peer-reviewed reports). RESULTS: In the 898 patients included in the study, 1359 PDDIs were identified in 426 patients (46%, 95% confidence interval (CI)=42-50%). In 143 patients (16%), a major PDDI was identified. The drug classes most frequently involved in a major PDDI were coumarins and opioids. The majority of cases concerned central nervous system interactions, PDDIs that can cause gastrointestinal toxicity and prolongation of QT intervals. In multivariate analysis, concomitant use of more drugs (odds ratio (OR)=1.66, 95% CI=1.54-1.78, P<0001) and genito-urinary cancer (OR=0.25, 95% CI=0.12-0.52, P<0001) were risk factors. CONCLUSION: Potential drug-drug interactions are very common among cancer patients on oral cancer therapy. Physicians and pharmacists should be more aware of these potential interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preventing Falls in Elderly Persons
Tinetti, M. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp020719 · Cited by 1,660
Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons
Woolcott, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.357 · Cited by 1,326
Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: I. Psychotropic Drugs
Leipzig, R. M., Cumming, R. G., & Tinetti, M. E. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01898.x · Cited by 1,153
A Physiological Profile Approach to Falls Risk Assessment and Prevention
Lord, S. R., Menz, H. B., & Tiedemann, A. (2003) · Physical Therapy · doi:10.1093/ptj/83.3.237 · Cited by 916
A physiological profile approach to falls risk assessment and prevention
(2007) · Falls in Older People · doi:10.1017/cbo9780511722233.018 · Cited by 886
Corticosteroid Use and Peptic Ulcer Disease: Role of Nonsteroidal Anti-inflammatory Drugs
Piper, J. M., Ray, W. A., Daugherty, J. R., & Griffin, M. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-735 · Cited by 608
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Self-citationYancik, R., & Ries, L. A. G. (2000) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70275-6 · Cited by 419
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., & Krzyzanowska, M. K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk130 · Cited by 328
A guideline for the treatment and prevention of NSAID-induced ulcers
Lanza, F. L. (1998) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00588.x · Cited by 276
Köhler, G. I., Bode-Böger, S. M., Busse, R., Hoopmann, M., Welte, T., & Böger, R. H. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38504 · Cited by 271
Tatro, D. S. (1990) · Cited by 254
Landi, F., Onder, G., Cesari, M., Barillaro, C., Russo, A., Bernabei, R., & on Behalf of the Silver Network Home Care Study Group (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.5.622 · Cited by 248
Singh, G., & Ramey, D. R. (1998) · PubMed · Cited by 242
A guideline for the treatment and prevention of nsaid-induced ulcers
Lanza, F. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00469-9 · Cited by 239
Fatal adverse drug events: the paradox of drug treatment
Buajordet, I., Ebbesen, J., Erikssen, J., Brors, O., & Hilberg, T. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00892.x · Cited by 219
Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence
Tascilar, M., de Jong, F. A., Verweij, J., & Mathijssen, R. H. J. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-732 · Cited by 200
Self-citationNCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R. N., Shapiro, C. L., Shields, A., Smith, M. R., Srinivas, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0076 · Cited by 198
Potential drug–drug interactions in the medication of medical patients at hospital discharge
Egger, S. S., Drewe, J., & Schlienger, R. G. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0557-z · Cited by 195
Overview of the changing paradigm in cancer treatment: Oral chemotherapy
Aisner, J. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070035 · Cited by 165
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Sideras, K., Ingle, J. N., Ames, M. M., Loprinzi, C. L., Mrazek, D. P., Black, J. L., Weinshilboum, R. M., Hawse, J. R., Spelsberg, T. C., & Goetz, M. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8931 · Cited by 145
Modulation of Irinotecan Metabolism by Ketoconazole
Kehrer, D. F. S., Mathijssen, R. H. J., Verweij, J., de Bruijn, P., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.177 · Cited by 137
Self-citationPotential drug interactions in cancer therapy: a prevalence study using an advanced screening method
van Leeuwen, R. W. F., Swart, E. L., Boven, E., Boom, F. A., Schuitenmaker, M. G., & Hugtenburg, J. G. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq761 · Cited by 135
Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic Review
Bourré‐Tessier, J., & Haraoui, B. P. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090153 · Cited by 131
Evaluation of personal digital assistant software for drug interactions
Barrons, R. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.4.380 · Cited by 122
Serotonin Syndrome Resulting from Coadministration of Tramadol, Venlafaxine, and Mirtazapine
Houlihan, D. J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d344 · Cited by 114
Glintborg, B., Andersen, S. E., & Dalhoff, K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0978-6 · Cited by 91
Yin, O. Q. P., Gallagher, N. J., Fischer, D., Demirhan, E., Zhou, W., Golor, G., & SCHRAN, H. F. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009346061 · Cited by 85
Serotonin Syndrome Caused by Selective Serotonin Reuptake-Inhibitors—Metoclopramide Interaction
Fisher, A. A., & Davis, M. W. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a161 · Cited by 66
Studying co‐medication patterns: the impact of definitions
Tobi, H., Faber, A., van den Berg, P. B., Drane, J. W., & den Berg, L. T. D. J.-V. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1304 · Cited by 56
Concomitant use of analgesics and psychotropics in home‐dwelling elderly people‐Kuopio 75 + study
Hartikainen, S. A., Mäntyselkä, P. T., Louhivuori-Laako, K. A., Enlund, H., & Sulkava, R. O. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02417.x · Cited by 53
Zarychanski, R. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl196 · Cited by 51
Tarumi, Y., Pereira, J., & Watanabe, S. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00368-2 · Cited by 46
Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis.
Seideman, P., & Müller-Suur, R. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.8.613 · Cited by 37
Verschraagen, M., Kedde, M. A., Hausheer, F. H., & van der Vijgh, W. J. F. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0610-3 · Cited by 22
Chan, A., Yap, K. Y., Koh, D., Low, X. H., Cheung, Y. T., & from the Onco‐Informatics (onco‐informatics.com) Group (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2167 · Cited by 17
Cited by
The impact of comorbidity on cancer and its treatment
Sarfati, D., Koczwara, B., & Jackson, C. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21342 · Cited by 680
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Metadata
- Authors
- van Leeuwen, R. W. F., Brundel, D. H. S., Neef, C., van Gelder, T., Mathijssen, R. H. J., Burger, D. M., & Jansman, F. G. A.
- Venue
- British Journal of Cancer
- Published
- 2013-02-14
- Volume
- 108
- Issue
- 5
- Pages
- 1071-1078
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2085393530
- Cited by
- 264
- References
- 38
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.